Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Prelude Therapeutics Incorporated (PRLD) had Consolidated Net Income/Loss of $-10.38M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$4.58M |
|
$-10.38M |
|
-- |
|
$4.58M |
|
$18.76M |
|
$-14.18M |
|
$3.79M |
|
$-10.38M |
|
$-10.38M |
|
$-10.38M |
|
$-10.38M |
|
|
Consolidated Net Income/Loss |
$-10.38M |
$-10.38M |
|
$-14.18M |
|
$-14.17M |
|
82.52M |
|
82.52M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$84.59M |
|
$4.72M |
|
$35.05M |
|
$119.64M |
|
$41.72M |
|
-- |
|
$17.74M |
|
$59.46M |
|
$60.18M |
|
$60.18M |
|
$60.18M |
|
63.02M |
|
| Cash Flow Statement Financials | |
$-21.68M |
|
$8.50M |
|
$-0.31M |
|
$38.49M |
|
$24.99M |
|
$-13.50M |
|
$2.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-309.54% |
|
-309.54% |
|
-- |
|
-226.75% |
|
-226.75% |
|
$-21.68M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-17.26% |
|
-17.26% |
|
-8.68% |
|
-17.26% |
|
$0.95 |
|
$-0.26 |
|
$-0.26 |
|